Avacopan

  • TRADE NAME: Tavneos (ChemoCentryx)
  • INDICATIONS:

    Adjunct for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy including glucocorticoids.


  • CLASS: Complement receptor antagonist
  • HALF-LIFE: 97.6 hours

FDA APPROVAL DATE: 10/07/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP3A4 inducers, CYP3A4 inhibitors, Itraconazole, Rifampin


No adequate and well-controlled studies with avacopan in pregnant women to inform a drug-associated risk.

Hepatitis B virus reactivation, including life threatening hepatitis B, was observed in the
clinical program.

Avacopan does not eliminate glucocorticoid use.

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 02/27/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top